ADMA Biologics Inc
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate is RI-002, a plasma-derived, polyclonal immune globulin intravenous that is in Phase III clinical study for the treatment of primary immune deficiency disease. The company also operatesADMA BioCenters Georgia, Inc, which is a plasma collection center. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.